Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313373372> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4313373372 endingPage "165.15" @default.
- W4313373372 startingPage "165.15" @default.
- W4313373372 abstract "Abstract Objective We discovered that IRF4 inhibits CD4 T cell dysfunction after transplantation (Immunity 47:1114). Here we study the role of IRF4 in regulating anti-tumor CD8 T cell response. Methods In model 1, different tumor cell lines were injected s.c. into mice with T cell-specific IRF4 deletion or control mice. In model 2, B16F10 melanoma-reactive Pmel-1 CD8 T cells were transduced with IRF4-GFP or GFP-control, and injected i.v. into congenic mice at 3 days post-s.c. injection of B16F10 cells. On day 14, T cell states in tumors were defined by single cell RNA-seq and flow cytometric analyses. Results IRF4 deletion in T cells significantly accelerated the progression of syngeneic TRAMP-C1 prostate cancer and B16F10 melanoma, and even enabled the growth of allogeneic CT26 Balb/c tumors. Adoptive transfer of IRF4-GFP transduced Pmel-1 T cells was significantly more potent than GFP-control transuded Pmel-1 cells in inhibiting B16F10 melanoma growth. In the GFP-control cell-transfer group, most Pmel-1 and endogenous CD8 T cells in tumors remained naïve-like or transitory states (expressed TCF1 but not effector molecules). In the IRF4-GFP cell-transfer group, more than half of Pmel-1 and endogenous CD8 T cells in tumors successfully developed into effector T cells that expressed multiple effector molecules. Conclusions IRF4 in T cells governs anti-tumor immunity. IRF4 overexpression in therapeutic T cells improves their anti-tumor potency." @default.
- W4313373372 created "2023-01-06" @default.
- W4313373372 creator A5019117674 @default.
- W4313373372 creator A5024962900 @default.
- W4313373372 creator A5041607266 @default.
- W4313373372 creator A5048918848 @default.
- W4313373372 creator A5068143805 @default.
- W4313373372 creator A5068707543 @default.
- W4313373372 creator A5071728228 @default.
- W4313373372 creator A5072810893 @default.
- W4313373372 creator A5081408506 @default.
- W4313373372 creator A5087578121 @default.
- W4313373372 creator A5089753425 @default.
- W4313373372 date "2020-05-01" @default.
- W4313373372 modified "2023-09-26" @default.
- W4313373372 title "IRF4 overexpression in therapeutic anti-tumor CD8 T cells inhibits tumor growth by driving functional state transition of therapeutic and endogenous CD8 T cells in tumors" @default.
- W4313373372 doi "https://doi.org/10.4049/jimmunol.204.supp.165.15" @default.
- W4313373372 hasPublicationYear "2020" @default.
- W4313373372 type Work @default.
- W4313373372 citedByCount "0" @default.
- W4313373372 crossrefType "journal-article" @default.
- W4313373372 hasAuthorship W4313373372A5019117674 @default.
- W4313373372 hasAuthorship W4313373372A5024962900 @default.
- W4313373372 hasAuthorship W4313373372A5041607266 @default.
- W4313373372 hasAuthorship W4313373372A5048918848 @default.
- W4313373372 hasAuthorship W4313373372A5068143805 @default.
- W4313373372 hasAuthorship W4313373372A5068707543 @default.
- W4313373372 hasAuthorship W4313373372A5071728228 @default.
- W4313373372 hasAuthorship W4313373372A5072810893 @default.
- W4313373372 hasAuthorship W4313373372A5081408506 @default.
- W4313373372 hasAuthorship W4313373372A5087578121 @default.
- W4313373372 hasAuthorship W4313373372A5089753425 @default.
- W4313373372 hasConcept C147483822 @default.
- W4313373372 hasConcept C154317977 @default.
- W4313373372 hasConcept C167672396 @default.
- W4313373372 hasConcept C202751555 @default.
- W4313373372 hasConcept C203014093 @default.
- W4313373372 hasConcept C2776090121 @default.
- W4313373372 hasConcept C2777658100 @default.
- W4313373372 hasConcept C502942594 @default.
- W4313373372 hasConcept C55493867 @default.
- W4313373372 hasConcept C86803240 @default.
- W4313373372 hasConcept C8891405 @default.
- W4313373372 hasConcept C90375314 @default.
- W4313373372 hasConceptScore W4313373372C147483822 @default.
- W4313373372 hasConceptScore W4313373372C154317977 @default.
- W4313373372 hasConceptScore W4313373372C167672396 @default.
- W4313373372 hasConceptScore W4313373372C202751555 @default.
- W4313373372 hasConceptScore W4313373372C203014093 @default.
- W4313373372 hasConceptScore W4313373372C2776090121 @default.
- W4313373372 hasConceptScore W4313373372C2777658100 @default.
- W4313373372 hasConceptScore W4313373372C502942594 @default.
- W4313373372 hasConceptScore W4313373372C55493867 @default.
- W4313373372 hasConceptScore W4313373372C86803240 @default.
- W4313373372 hasConceptScore W4313373372C8891405 @default.
- W4313373372 hasConceptScore W4313373372C90375314 @default.
- W4313373372 hasIssue "1_Supplement" @default.
- W4313373372 hasLocation W43133733721 @default.
- W4313373372 hasOpenAccess W4313373372 @default.
- W4313373372 hasPrimaryLocation W43133733721 @default.
- W4313373372 hasRelatedWork W1649281945 @default.
- W4313373372 hasRelatedWork W2008057646 @default.
- W4313373372 hasRelatedWork W2054101033 @default.
- W4313373372 hasRelatedWork W2055715607 @default.
- W4313373372 hasRelatedWork W2072008518 @default.
- W4313373372 hasRelatedWork W2159389701 @default.
- W4313373372 hasRelatedWork W2174267452 @default.
- W4313373372 hasRelatedWork W2216689108 @default.
- W4313373372 hasRelatedWork W2263755362 @default.
- W4313373372 hasRelatedWork W2480226770 @default.
- W4313373372 hasVolume "204" @default.
- W4313373372 isParatext "false" @default.
- W4313373372 isRetracted "false" @default.
- W4313373372 workType "article" @default.